(490a) Developing a Novel Platform for Synthetic Peptide Manufacture Using Continuous Synthesis Methodologies

Kevin is a technical VP/Senior Fellow with Lilly and holds a PhD in Chemical Engineering. He has over 25 years’ experience working in small and medium molecule syntheses for both Merck and Eli Lilly. Kevin has been responsible for the process development and optimization of many early as well as late phase products and led the technology transfer, validation, and launch of several marketed compounds. Kevin has also led initiatives for developing enhanced filings in support of the ICH QbD and continuous processing initiatives. Most recently, Kevin led the late phase development team responsible for the commercialization of Lilly’s Mounjaro. Kevin has worked closely with expert teams within Lilly to implement a strategy for synthesizing peptides using a standardized manufacturing platform and applying the strategy to Lilly’s growing peptide portfolio.

Currently Kevin is a Fellow with the American Institute of Chemical Engineers, and Chair of the PD2M forum within AIChE, driving the application of chemical engineering principles to discovery, development and manufacturing within the pharmaceutical industry.